Meeting
2022 ASCO Annual Meeting
The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results.
Authors
Nitin Ohri
Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
Nitin Ohri , Shruti Jolly , Benjamin T. Cooper , Rafi Kabarriti , William Raymond Bodner , Jonathan Klein , Shankar Viswanathan , Elaine Shum , Joshua K. Sabari , Haiying Cheng , Rasim A. Gucalp , Enrico Castellucci , Angel Qin , Shirish M. Gadgeel , Balazs Halmos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03523702
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8510)
DOI
10.1200/JCO.2022.40.16_suppl.8510
Abstract #
8510
Poster Bd #
137
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
The selective personalized radioimmunotherapy for locally advanced NSCLC trial (SPRINT).
First Author: Nitin Ohri
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2022 ASCO Annual Meeting
Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.
First Author: Jarushka Naidoo
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto